Your browser doesn't support javascript.
Vulnerability of SARS-CoV-2 and PR8 H1N1 virus to cold atmospheric plasma activated media.
Cortázar, Osvaldo Daniel; Megía-Macías, Ana; Moreno, Sandra; Brun, Alejandro; Gómez-Casado, Eduardo.
  • Cortázar OD; University of Castilla-La Mancha, Institute of Energy Research (INEI), C/Moledores s/n., 13071, Ciudad Real, Spain. daniel.cortazar@uclm.es.
  • Megía-Macías A; Mechanical Engineering Department, ICAI, Comillas Pontifical University, Alberto Aguilera 25, 28015, Madrid, Spain.
  • Moreno S; Institute for Research in Technology, ICAI, Comillas Pontifical University, Santa Cruz de Marcenado, 26, 28015, Madrid, Spain.
  • Brun A; Animal Health Research Center (CISA, INIA-CSIC), National Research Institute of Agricultural and Food Technology (CSIC-INIA), Crta. de Valdeolmos-El Casar s/n - 28130, Madrid, Spain.
  • Gómez-Casado E; Animal Health Research Center (CISA, INIA-CSIC), National Research Institute of Agricultural and Food Technology (CSIC-INIA), Crta. de Valdeolmos-El Casar s/n - 28130, Madrid, Spain. brun@inia.es.
Sci Rep ; 12(1): 263, 2022 01 07.
Article in English | MEDLINE | ID: covidwho-1612211
ABSTRACT
Cold Atmospheric Plasma (CAP) and Plasma Activated Media (PAM) are effective against bacteria, fungi, cancer cells, and viruses because they can deliver Reactive Oxygen and Nitrogen Species (RONS) on a living tissue with negligible damage on health cells. The antiviral activity of CAP against SARS-CoV-2 is being investigated, however, the same but of PAM has not been explored despite its potential. In the present study, the capability of Plasma Activated Media (PAM) to inactivate SARS-CoV-2 and PR8 H1N1 influenza virus with negligible damage on healthy cells is demonstrated. PAM acted by both virus detaching and diminished replication. Furthermore, the treatment of A549 lung cells at different times with buffered PAM did not induce interleukin 8 expression, showing that PAM did not induce inflammation. These results open a new research field by using PAM to the development novel treatments for COVID-19, influenza, and other respiratory diseases.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Influenza A Virus, H1N1 Subtype / Plasma Gases / SARS-CoV-2 Limits: Humans Language: English Journal: Sci Rep Year: 2022 Document Type: Article Affiliation country: S41598-021-04360-y

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Influenza A Virus, H1N1 Subtype / Plasma Gases / SARS-CoV-2 Limits: Humans Language: English Journal: Sci Rep Year: 2022 Document Type: Article Affiliation country: S41598-021-04360-y